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Abstract
Background: Infiltrating immune cells including monocytes/macrophages have been implicated in the pathogenesis
of neovascular age-related macular degeneration (nAMD). The aim of this study was to investigate the cytokine and
chemokine expression and secretion profile of peripheral blood mononuclear cells (PBMCs) from nAMD patients and
the relationship between the cytokine/chemokine expression profile and clinical phenotype of nAMD, including
macular fibrosis, macular atrophy or the responsiveness to anti-VEGF therapy.
Methods: One hundred sixty-one nAMD patients and 43 controls were enrolled in this study. nAMD patients
were divided into subgroups based on the presence/absence of (1) macular atrophy, (2) macular fibrosis and (3)
responsiveness to anti-VEGF therapy; 25–30 ml of peripheral blood were obtained from all participants and 5 ml
were used for serum collection, and the remaining were used for PBMC isolation using density gradient centrifugation.
Intracellular cytokine expressions by PBMCs following phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation
were examined using flow cytometry. Cytokine productions in lipopolysaccharides (LPS)-or 1% oxygen -treated PBMC
were measured using cytometric bead array (CBA) assay. In addition, cytokine and chemokine levels in the serum were
also measured by CBA assay.
Results: PBMCs from nAMD patients secreted higher levels of IL-8, CCL2 and VEGF, especially following LPS and 1%
oxygen stimulation, than those from controls. 60~80% of IL-8 producing cells were CD11b+CD3− monocytes. The
percentage of CD11b+CD3− IL-8+ was significantly increased in nAMD patients compared to controls. PBMCs from
nAMD patients without macular fibrosis produced the highest levels of IL-8 and CCL2, whilst PBMCs from nAMD patients
with macular atrophy produced highest levels of VEGF. In addition, PBMCs from patients who partially responded
to anti-VEGF produced higher levels of IL-8 compared to the cells from complete responders. Interestingly, serum
level of CCL2 was not increased in nAMD patients although there was a trend of increased IL-8 in nAMD patients.
Conclusions: PBMCs, in particular monocytes, may contribute to CNV development in nAMD through secreting
elevated levels of IL-8, CCL2 and VEGF after they are recruited to the macula. Apart from VEGF, IL-8 and CCL2 may
be additional targets for nAMD management.
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Background
Age-related macular degeneration (AMD) is the leading
cause of blindness in the elderly in the developed world.
Patients with AMD may present with degeneration of reti-
nal pigment epithelium (RPE) and choroid (geographic
atrophic, GA) or neovascular membrane and retina and/
or RPE detachment (neovascular AMD, nAMD) in the
macula. Leakage from neovascular membrane causes
macular oedema and visual impairment. Currently,
nAMD is treated by intravitreal injections of VEGF in-
hibitors including ranibizumab (Lucentis, Genentech,
San Francisco, CA), bevacizumab (Avastin, Roche,
Basel, Switzerland) and more recently aflibercept (Eylea,
Regeneron, Tarrytown, NY). Although the therapy can
stabilize the disease and even improve vision, not all pa-
tients respond to the treatment [1], suggesting that
multiple pathways may be involved in the pathogenesis of
nAMD.
Epidemiological and genetic studies have shown that
ageing, environmental factors (e.g. tobacco smoking,
diet, hypertension, cardiovascular disease) [2, 3] as well
as gene polymorphisms (e.g. complement-related genes
(CFH, C3), Toll-like receptors (TLRs) and chemokine re-
ceptors (CX3CR1)) [4–7] increase the risk of AMD.
Many of the genes involved in AMD are associated with
the immune system, suggesting that dysregulated immune
response or inflammation may contribute to AMD aetio-
logy, and this concept is now well appreciated and
supported by multiple observations [8]. Inflammatory
molecules, including complement components, immuno-
globulins and C-reactive protein, have been detected in
drusen deposits of AMD patients [9]. Drusen particles or
its constituents, such as amyloid beta, can induce inflam-
masome activation and inflammatory cytokine expression
(IL-1β and IL-8) in macrophages and RPE cells [10].
Additionally, inflammatory cytokines (IL-6 and IL-8)
have been detected in the aqueous humour of nAMD
patients [11].
Inflammation is generally considered as a protective
response to infection and tissue injury. When the mac-
ula is damaged due to old age and environmental risk
factor-mediated oxidative insults, tissue resident im-
mune cells including retinal microglia and choroidal
macrophages as well as the complement system may be
activated to repair damage and maintain macular
function. In addition, circulating immune cells may be
recruited to participate in macular inflammation [12].
How the tissue-protective immune response becomes
detrimental and induces angiogenesis in nAMD remains
unknown. It is believed that the macular microenviron-
ment (high levels of oxidative lipids/proteins and hypoxia)
may critically control the level and type of immune re-
sponse in the ageing eye. We hypothesize that, in addition
to macular microenvironment, immune cells in nAMD
patients may have a disease-causing phenotype that
makes them more pro-inflammatory or angiogenic once
recruited to the damaged macula. A recent transcrip-
tome analysis of monocytes has revealed a systemic in-
flammatory signature in monocytes from nAMD
patients [13]. Monocytes from nAMD patients have
been shown to express higher levels of chemokine re-
ceptor CCR1, CCR2 and CX3CR1 [14] and the activa-
tion marker HLA-DR and phosphorylated STAT3 [15].
We have also found that nAMD patients have higher
levels of circulating neutrophils [16].
This study was performed to investigate the cytokine/
chemokine expression and secretion profile of peripheral
mononuclear cells (i.e. monocytes and lymphocytes)
from nAMD patients. Considering the diversity of the
AMD phenotype as well as the mixed response to anti-
VEGF therapy [17], it is feasible that different immune
mechanisms may be involved in different types of nAMD.
Therefore, we further investigated whether the cytokine
profile in nAMD patients was associated with the develop-
ment of macular fibrosis, macular atrophy or the response
to anti-VEGF therapy.
Methods
Study participants
The study protocol was approved by the Research Ethics
Committee of Queen’s University Belfast and procedures
were performed in accordance with the tenets of the
Declaration of Helsinki on research into human volun-
teers. Participants were recruited from the macular
disease clinics in Belfast (Belfast Health and Social Care
Trust, UK) with written informed consent obtained from
each participant. Spouses, relatives or friends who accom-
panied patients and who were confirmed to be without
retinal disease (colour fundus photography (CFP) and
optical coherence tomography (OCT)) were recruited as
controls. All participants were older than 50 years of age
and structured questionnaires were used to ascertain a
history of medical conditions, current medication, family
history of AMD, smoking habits (current, former smoker,
never smoker) and body mass index (BMI). Participants
with systemic inflammatory or autoimmune disorders (e.g.
patients with active rheumatoid arthritis or active chronic
bronchitis) and participants undergoing steroid therapy or
chemotherapy were excluded from the study.
The diagnosis of nAMD was by clinical examination and
confirmed by multimodal imaging consisting of fundus
photography, autofluorescence, OCT, fluorescein angiog-
raphy and indocyanine green angiography. In this study,
most of the participants (158 of 161) were receiving anti-
VEGF therapy prior to enrolment. The number of anti-
VEGF (ranibizumab, trade name Lucentis, Genentech, San
Francisco, CA) injections received by each patient prior to
blood collection was ascertained from the medical records.
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Participants with nAMD were followed up for 6 months,
and we graded colour images and tomographic scans of
the recruited participants at their most recent visit prior
to closure of the database. Responsiveness to treatment
was defined based on the participant achieving a fluid-free
macula at any stage during follow-up. In addition, the
status of whether a patient was fluid free at the month 3
and month 6 examinations was also recorded. Partici-
pants were classified into the following three categories:
complete responder: resolution of leakage at any point
in time during follow up; partial responder: exhibiting
dependence on VEGF inhibitors but a fluid-free macula
never achieved; and non-responder: no morphological
improvement or worsening. Macular scar identification
was based on both colour and OCT characteristics. On
colour fundus photographs, macular scar was defined
as well-delineated areas of yellowish-white tissue which
on OCT corresponded to the presence of linear bands
of hyperreflective material that had either obscured or
replaced the normal reflectivity and banding of the neu-
rosensory retina and RPE/Bruch's membrane complex.
Macular atrophy (MA) was defined as single or mul-
tiple areas of hypopigmentation with well-defined bor-
ders and visible large choroidal vessels on CFP which
corresponded to window defects on angiography and/
or to the loss of cellular layers (outer retina, RPE and
choriocapillaris) on the accompanying tomograms.
Participant samples were assigned randomly for ex-
perimental analysis with some samples being included in
more than one analysis. Three experimental analyses
were undertaken with the repository of blood samples.
Experiment 1 investigated cytokines/chemokines in the
serum (133 nAMD and 43 controls samples); experiment 2
investigated secreted cytokines/chemokines by peripheral
blood mononuclear cells (PBMCs) (75 nAMD and 28 con-
trol samples) and experiment 3 investigated the intracellu-
lar cytokine/chemokine expression by PBMCs (28 nAMD
and 27 control samples).
Serum collection
Venous blood (5 ml) was collected in tubes containing
serum clot activator and centrifuged at 2000 g for 15 min
within 3 h of collection. After centrifugation, the serum
was aliquoted and stored at −80 °C until analysis.
PBMC isolation and culture
Whole blood collected (20–25 ml) in tubes containing
ethylenediaminetetraacetic acid (EDTA) as anticoagu-
lant between 9:00 am and 12:00 noon was processed
within 3 h of collection. PBMCs were isolated by Ficoll-
Paque (Histopaque 1077; Sigma-Aldrich, Gillingham,
UK) density gradient centrifugation (400 g for 30 min
at RT with the break turned off) and washed twice with
PBS (300 g for 10 min at 4 °C). PBMCs were resuspended
at 2.5 × 106 cells/ml in RPMI 1640 medium containing
10% FCS and 1% penicillin-streptomycin and cultured
in 24-well plates (500 μl/well) and treated immediately
with lipopolysaccharides (LPS) (2.5 μg/ml; Sigma-Aldrich)
or exposure to hypoxia (1% oxygen) for 16 h. The superna-
tants for PBMC cultures were collected, centrifuged for
5 min at 300 g at 4 °C, and aliquoted and stored at
−80 °C until analysis.
Cytometric bead array
Cytokines were measured in the serum by cytometric bead
array (CBA) using CBA Flex Sets (CD121a, CD121b,
MCP-1, VEGF, TGFβ1, GM-CSF and IFNα) and CBA
Enhanced Sensitivity Flex Sets (IFNγ, IL-2, IL-4, IL-6, IL-8,
IL-10, IL12p70, IL-17A and TNFα) (BD Biosciences,
Oxford, UK) according to the manufacturer’s instructions.
Cytokines in PMBC supernatant were measured using a
CBA Human Th1/Th2/Th17 Cytokine Kit (IL-2, IL-4, IL-6,
IL-10, TNFα, IFNγ and IL-17A) and CBA Flex Sets
(CD121a, CD121b, MCP-1, VEGF, GM-CSF and IL-8) (BD
Biosciences) according to the manufacturer’s instructions
and as described previously [15]. For cell culture superna-
tants, the total protein concentration was measured using a
Pierce BCA protein assay kit (Thermo Scientific, Loughbor-
ough, UK) according to the manufacturer’s instructions.
The concentrations of the cytokines were normalized to
the total protein concentration (pg/mg total protein). TGF-
β1 was measured as a single plex assay and serum samples
were activated by incubation with 2.5 N acetic acid/8 M
urea for 10 min at RT followed by neutralization with 2.7 N
NaOH/1 M HEPES prior to CBA assay according to the
manufacturer’s instructions.
Intracellular cytokine expression of PBMC by flow
cytometry
PBMCs were stimulated for 4 h with phorbol 12-myristate
13-acetate (PMA; 100 ng/ml; Sigma-Aldrich) and ionomy-
cin (1 μg/ml; Sigma-Aldrich) in the presence of 1× monen-
sin (BioLegend, UK). After incubation, cells were stained
with fluorochrome-labelled antibodies (anti-human CD3-
FITC (BD Biosciences), CD3-PE-Cy7, IL-17A-PE, IL-4-
APC, IL-6-APC (eBiosciences, San Diego, USA ), IFNγ-
APC-Cy7, IL-8-PE, IL-10-Brilliant violet 421 and CD11b-
APC-Cy7 (BioLegend, London, UK)).
Briefly, PBMC were washed twice with FACS buffer
(300 g for 5 min at 4 °C) and resuspended at 10 × 106
cells/ml; 20 μl (2 × 105 cells) were dispensed per FACS
tube and incubated with 5 μl Human TruStain FcX (Fc
Receptor blocking solution; BioLegend) for 5 min at RT.
The cells were then incubated with cell surface antibodies
in a total volume of 100 μl FACS buffer for 30 min in the
dark at 4 °C. After staining, cells were washed twice
with FACS buffer and then fixed and permealized using
the Foxp3 Transcription factor Staining Buffer Set
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(eBiosciences) according to the manufacturer’s
instructions. Samples were then incubated with 5 μl
Human TruStain FcX (Fc Receptor blocking solution;
BioLegend) followed by incubation with intracellular
cytokine antibodies in a total volume of 100 μl permea-
lization buffer (eBiosciences) for 40 min in the dark at
4 °C. Cells were washed and acquired on the FACSCan-
toII flow cytometer (BD Biosciences). Data analysis was
performed blindly using FlowJo software version 10.07
for Windows (Tree Star, Oregon, USA).
Gating was performed by first dividing PBMCs into
CD11b+CD3−, CD11b−CD3+ and CD11b−CD3− cells
(Fig. 2). Gates for intracellular cytokines IL-4, IL-6, IL-8,
IL-10, IL-17A and IFNγ were set on total live cells based
on the unstained control, and the same gates were then
applied to CD11b+CD3−, CD11b−CD3+ and CD11b−CD3−
cell subsets.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences, Windows version 21
(SPSS Inc, Armonk, NY). Categorical demographic and
clinical data were compared using Pearson’s chi-square
test. The distribution of continuous variables was
assessed for normality using the Kolmogorov-Smirnov
test, and logarithmic transformation was performed if
necessary to achieve normal distribution. Normally
distributed continuous samples were then compared
using the independent samples t test or one-way ANOVA.
Age was not normally distributed and the difference be-
tween controls and nAMD patients was analysed using
the Mann-Whitney U test.
For the associations that were significant in the univar-
iate analysis, multinomial logistic regression was per-
formed to adjust for age and gender. All variables were
also tested for association with family history of AMD,
history of cardiovascular disease, history of hypertension,
history of diabetes, smoking habits, BMI, taking of car-
diovascular medication, vitamins and low-dose aspirin
using the independent samples t test, one-way ANOVA
or Pearson’s correlation. If significant associations were
identified, adjustments were made in the multinomial
logistic regression analysis. Pearson’s correlation was
used to assess the correlation between the number of
anti-VEGF injections a patient had received prior to
blood collection and the different variables analysed
(e.g. cytokine serum levels, secreted cytokine levels and
intracellular cytokine levels). Data in figures are pre-
sented as mean + standard error of the mean (SEM)
calculated from untransformed variables even if the
statistical analysis was performed on transformed variables.
P values <0.05 were considered statistically significant.
Results
Clinical evaluation
There was a significant difference in age between con-
trols and nAMD patients in experiment 1 (P = 0.001)
(Additional file 1: Table S1), but not in experiments 2
(Table 1) and 3 (data not shown). In all three experiments,
Table 1 Demographic and clinical characteristics of nAMD patients and controls from secreted cytokines analysis (experiment 2)
All
(n = 103)
Controls
(n = 28)
nAMD
(n = 75)
P value
nAMD vs control
Age (median (range)), years 77.2 (57–93) 74.5 (59–92) 78.1 (57–93) 0.066a
Female sex (number (%)) 58 (56) 14 (50) 44 (59) 0.505b
Family history of AMD (number (%)) 25 (24) 4 (14) 21 (28) 0.202b
Cardiovascular disease (number (%)) 27 (26) 6 (21) 21 (28) 0.621b
Hypertension (number (%)) 62 (60) 12 (43) 50 (67) 0.065b
Diabetes (number (%)) 12 (12) 1 (4) 11 (15) 0.175b
Body mass index (mean ± SD) 25.8 (4.0) 25.2 (3.8) 26.1 (4.0) 0.318c
Smoking status 0.883b
Non-smoker (number (%)) 40 (39) 12 (43) 28 (37)
Former smoker (number (%)) 54 (52) 13 (46) 41 (55)
Current smoker (number (%)) 8 (8) 2 (7) 6 (8)
Taking medication for CVD (number (%)) 73 (71) 17 (61) 56 (75) 0.320b
Vitamin supplementation (number (%)) 21 (20) 2 (7) 19 (25) 0.055b
Taking low-dose aspirin (number (%)) 33 (32) 3 (11) 30 (40) 0.008b
Italics P < 0.05
SD standard deviation
aMann Whitney U test
bPearson’s chi-square test
cIndependent samples t test
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there were no significant differences regarding gender dis-
tribution, family history of AMD, history of cardiovascular
disease, history of hypertension, history of diabetes, BMI
and smoking habits between controls and nAMD patients.
In the serum analysis, there were more nAMD patients
taking vitamins compared to controls (Additional file 1:
Table S1). Vitamin intake was not significantly increased
in experiments 2 and 3 although there was a trend of
more participants taking vitamins in the nAMD group
compared to controls (Table 1) in both studies. Low-dose
aspirin intake was significantly higher in nAMD patients
when compared to controls in all three studies (Table 1
and Additional file 1: Table S1).
Of all patients enrolled, the average duration between
the last anti-VEGF treatment and the day of blood
collection was 112.5 ± 142.2 days (interquartile range
40.0–118.0 days). No participant had received anti-
VEGF treatment within 4 weeks prior to blood collec-
tion. The average number of anti-VEGF injections received
per nAMD patient prior to blood collection was 15.2 ±
10.3 (interquartile range 8.0–20.0). There was no correl-
ation between the number of anti-VEGF injections re-
ceived and any of the variables analysed.
Cytokine levels in the serum in nAMD patients and
controls
Of all cytokines measured in the serum IL-8, CD121a,
CD121b, CCL2, TGF-β1 and VEGF were detectable
whilst the remaining cytokines were below the detection
limit (GM-CSF and IFNα <10 pg/ml; IFNγ, IL-2, IL-4,
IL-6, IL-10, IL-12p70, IL-17 and TNFα <0.3 pg/ml).
There were no significant differences in serum cytokine
levels when comparing nAMD patients to controls,
although there was a trend of increased IL-8 production
in nAMD patients (Table 2).
Cytokine production by PBMCs from nAMD and controls
Of all cytokines measured in the supernatants of PBMC
cultures, IL-10, TNFα, CCL2, IL-6, IL-8 and VEGF were
detectable whilst the remaining cytokines were below
the detection limit (CD121a and CD121b <40 pg/ml; GM-
CSF <10 pg/ml; IL-2, IL-4, IFNγ and IL-17A <20 pg/ml).
Under non-stimulated conditions, PBMCs from nAMD
patients appeared to secrete higher levels of CCL2 and IL-
8 although statistically insignificant when compared to
controls (Fig. 1a). VEGF was significantly increased in
PBMC supernatants from nAMD compared to controls in
both univariate and multivariate (adjusting for age and
gender) analyses (Fig. 1a).
Following LPS stimulation the production of IL-10,
TNFα, IL-6, and IL-8 was significantly increased (Fig. 1b
vs Fig. 1a). There was a significant increase in CCL2, IL-8
and VEGF in PBMC supernatants from nAMD patients
compared to controls in the univariate and multivariate
analysis (corrected for age and gender, as well as low-dose
aspirin intake) (Fig. 1b). Interestingly, IL-6 production was
significantly reduced in PBMC supernatants from nAMD
patients compared to controls following LPS stimulation.
The 1% oxygen treatment significantly increased the
production of VEGF but not other cytokines in PBMC
from both control and nAMD patients (Fig. 1c vs Fig. 1a).
Under 1% oxygen condition, PBMCs from nAMD patients
secreted more IL-8 and VEGF compared to those from
controls in both univariate and multivariate analysis
(Fig. 1c).
Taken together, our results show that PBMCs from
nAMD patients produce more angiogenic growth factor
VEGF and chemokines MCP-1 (CCL2) and IL-8 (CXCL8)
than those from healthy controls, particularly under
inflammatory conditions (e.g. LPS stimulation).
Intracellular cytokine production by PBMC
To further understand which subsets of PBMC produced
higher levels of IL-8 in nAMD patients, we examined
intracellular cytokine expression using flow cytometry.
Cell surface antigens CD11b and CD3 were used to dif-
ferentiate CD11b+CD3− (predominately monocytes),
CD11b−CD3+ (predominately T cells) and CD11b−CD3−
cells (predominately B cells) (Additional file 2: Figure S1A).
Naïve PBMCs consisted of ~20% CD11b+CD3− cells, 50–
60% CD11b−CD3+ and 20–30% CD11b−CD3− cells. After
simulation with PMA/ionomycin for 16 h, there was a
slight shift towards more CD11b−CD3− cells and less
CD11b+CD3− cells in both nAMD patients and controls
(Additional file 2: Figure S1B). This shift towards a
lower percentage of monocytes following PMA/iono-
mycin stimulation has been reported previously (~22%
CD14+ cells before stimulation vs 12% CD14+ cells after
stimulation) [18].
In naïve non-stimulated PBMCs, the percentage of IL-
8-producing cells was significantly increased in nAMD
patients compared to controls in univariate (P = 0.017)
but not multivariate analysis (adjusting for age, gen-
der, cardiovascular drug and low-dose aspirin intake,
Table 2 Serum cytokine levels in nAMD patients and controls
Variables
(pg/ml)
Controls
(mean ± SD)
n = 43
nAMD
(mean ± SD)
n = 133
P value
nAMD vs controlsa
IL-8 12.63 ± 9.78 18.17 ± 23.85 0.090
CD121a 1315.88 ± 924.68 1353.27 ± 988.96 0.829
CD121b 2601.10 ± 1601.77 2477.91 ± 1313.55 0.652
CCL2 177.00 ± 253.49 138.57 ± 77.25 0.380
TGF-β1 7930.12 ± 4467.25 8200.52 ± 3613.87 0.757
VEGF 68.18 ± 56.49 92.67 ± 89.07 0.117
SD standard deviation
aIndependent samples t test
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P = 0.089, Fig. 2a). After stimulation with PMA/ionomy-
cin, the percentage of IL-8 producing cells remained
higher in nAMD patients compared to controls; however,
the difference was not statistically significant. Further ana-
lysis showed that 60–80% of IL-8-producing cells were
CD11b+CD3− monocytes (Fig. 2b), suggesting that mono-
cytes are the major sources of IL-8 production in PBMC
cultures. Following PMA/ionomycin treatment, signifi-
cantly higher populations of CD11b+CD3− cells produced
IL-8 in both controls and nAMD patients (Fig. 2c). The
percentage of IL-8-producing CD11b+CD3− cells was sig-
nificantly higher in nAMD patients compared to controls
after PMA/ionomycin stimulation in both univariate and
multivariate analysis (Fig. 2c). In addition, the percentage
of IL-8-producing CD11b−CD3+ T cells was higher in
nAMD patients (5.0 ± 4.3%) compared to controls (2.9 ±
2.5%) in the univariate (P = 0.038 ), but not multivariate
analysis (P = 0.117, adjusting for age, gender and diabetes).
Our results suggest that increased IL-8 production by
PBMCs (Fig. 2) in nAMD patients may attribute pre-
dominately to CD11b+CD3− monocytes.
Although there was no significant difference in IL-6
levels in PBMC supernatants from non-stimulated cells
between nAMD and controls (Fig. 1a), the population of
IL-6 producing cells, in particular CD11b+CD3−IL-6+
cells, was significantly increased in nAMD patients under
non-stimulatory conditions (Fig. 3).
There were no significant differences between nAMD
and controls in IL-4, IL-10, IFNγ or IL-17A producing
cells under naïve or PMA/ionomycin treatment condi-
tions (Additional file 2: Figure S2).
The production of CCL2 and IL-8 by PBMCs and macular
fibrosis
To understand the link between CCL2/IL-8 and macular
fibrosis, nAMD patients were sub-grouped into fibrosis
Fig. 1 Cytokine secretion by PBMC. IL-10, TNFα, CCL2, IL-6, IL-8 and VEGF secretion in the supernatant of PBMCs from controls and nAMD patients
under non-stimulated conditions (a), following LPS treatment (b) and under hypoxic conditions (c). Controls n = 28, nAMD n = 75; mean + SEM;
#P < 0.05, ##P < 0.01 in univariate analysis using independent samples t test; *P < 0.05, **P < 0.01 in multivariate analysis using multinomial
logistic regression
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absent (−) and present (+). PBMCs from fibrosis (−)
patients secreted the highest levels of CCL2 and IL-8
compared to cells from other groups (Fig. 4), particularly
after LPS stimulation (Fig. 4b). The higher level of IL-8
by PBMCs from fibrosis (−) patients was further con-
firmed by intracellular cytokine staining (Fig. 4d). Secreted
VEGF levels were similar in both patient groups and were
elevated when compared to controls (Fig. 4).
No differences were observed for IL-10, TNFα and IL-6
levels produced by PBMCs between different groups of
nAMD patients and controls.
Cytokine production by PBMC and MA
Amongst the 75 nAMD patients whose cytokine produc-
tion by PBMCs was studied, information regarding MA
at the time of sample collection was available from 52
patients, of which 35 had MA and 17 did not have MA.
The level of CCL2 in PBMC supernatants did not appear
to be related to the presence or absence of MA (Fig. 5).
IL-8 was significantly increased in nAMD patients with
MA compared to controls following LPS stimulation.
Interestingly, higher levels of VEGF production by
PBMC, particularly after LPS stimulation, appeared to
be related to MA development (Fig. 5b). The number of
anti-VEGF injections appeared to be higher in the MA
present group compared to the MA absent group
although statistically insignificant (P = 0.056).
Cytokine production by PBMCs and response to
anti-VEGF therapy
Of the 75 nAMD patients whose PBMCs were studied,
41 responded partially, 32 responded completely and 2
did not respond to anti-VEGF (ranibizumab/Lucentis)
therapy. No significant differences were found when
comparing secreted cytokine levels in the PBMC superna-
tants from patients partially and completely responding to
anti-VEGF therapy. Following PMA/ionomycin stimula-
tion, the population of IL-8-producing cells was increased
in partial responders compared to complete responders in
the univariate but not multivariate analysis (Fig. 6). The
non-responder group was not included in the statistical
analysis due to low sample size (n = 2).
Fig. 2 IL-8 producing PBMCs under non-stimulated conditions and after stimulation with PMA/ionomycin. Percentage of total IL-8 producing
PBMCs from controls and nAMD patients (a) and composition of IL-8 producing cells from all samples (b). Percentage of CD11b+CD3- cells that
were positive for intracellular IL-8 from controls and nAMD patients (c). Controls n = 27, nAMD = 28; mean + SEM; #P < 0.05, ##P < 0.01 in univariate
analysis suing independent samples t test; *P < 0.05 in multivariate analysis using multinomial logistic regression
Fig. 3 IL-6 producing PBMCs under non-stimulated conditions and after stimulation with PMA/ionomycin. Percentage of total (a) and CD11b+CD3- (b)
IL-6 producing PBMCs from controls and nAMD patients. Controls n = 27, nAMD= 28; mean + SEM; ##P < 0.01 in univariate analysis using independent
samples t test; *P < 0.05 in multivariate analysis using multinomial logistic regression
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Discussion
Inflammation is known to play a critical role in the
development of choroidal neovascularisation in AMD
although the underlying mechanism is not fully under-
stood [8, 19, 20]. Inflammatory cells may migrate from
surrounding tissues including the neuronal retina (i.e.
microglia) and choroid to the macula or be recruited
from circulating immune cells [12]. In this study, we
provide evidence that PBMCs, in particular monocytes
from nAMD patients, produce increased levels of IL-8,
CCL2 and VEGF, especially under inflammatory condi-
tions. Our results suggest that PBMCs in nAMD pa-
tients may contribute to the development of macular
angiogenic lesions through producing excessive amounts
of IL-8, CCL2 and VEGF.
IL-8 (CXCL8), an important inflammatory cytokine
and potent angiogenic factor, has previously been linked
to the pathogenesis of AMD. Single-nucleotide poly-
morphisms (SNPs) in the IL-8 regulatory and coding
regions have been associated with increased risk of
AMD [21–23] and certain SNP genotypes have been
linked to increased IL-8 serum levels [24]. Exactly how
IL-8 contributes to AMD pathology is not known. Pre-
vious studies have reported elevated levels of IL-6, IL-8
and CCL2 in the aqueous humour from nAMD patients
[25], and the levels correlated with choroidal neovascu-
larisation (CNV) lesion size [26]. Although retinal cells,
including microglia, vascular endothelial cells [27] and
RPE cells [28], can produce IL-8, our results suggest
that infiltrating immune cells, especially CD11b+CD3−
Fig. 4 Cytokine production and macular fibrosis. CCL2, IL-8 and VEGF levels in PBMC supernatants under non-stimulated condition (a), following
LPS treatment (b) and under hypoxic condition (c) as well as percentage of total IL-8 producing PBMCs under non-stimulated conditions (d) from
healthy controls and nAMD patients without and with fibrosis. Supernatants: controls, n = 28, fibrosis (−), n = 54, fibrosis (+), n = 21; PBMC:
controls, n = 27, fibrosis (−), n = 15, fibrosis (+), n = 13; mean + SEM; #P < 0.05, ##P < 0.01, ###P < 0.001 in univariate analysis using one-way
ANOVA; *P < 0.05, **P < 0.01 in multivariate analysis using multinomial logistic regression
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monocytes may contribute to increased intraocular IL-8
production in nAMD.
IL-8 is known to be involved in both physiological and
pathological angiogenesis through its receptors CXCR1
and CXCR2 [29]. The pro-angiogenic effect of IL-8 on
endothelial cells is mediated partially through the induc-
tion of VEGFR2 and VEGF-A expression [30] although a
VEGF-independent pathway has also been reported [31].
IL-8 production has been associated with resistance to
anti-VEGF therapy in tumours, further supporting a
VEGF-independent pro-angiogenic mechanism for IL-8
[32]. In this study, we observed increased levels of IL-8
by PBMCs from nAMD patients who are partially resistant
to anti-VEGF therapy compared to PBMCs from complete
Fig. 5 Cytokine production and macular atrophy. CCL2, IL-8 and VEGF levels in PBMC supernatants from healthy controls and nAMD patients
without and with macular atrophy (MA) under non-stimulated condition (a), following LPS treatment (b) and under hypoxic condition (c). Controls
n = 28, MA (−) n = 17, MA (+) n = 35; mean + SEM; #P < 0.05, ##P < 0.01 in univariate analysis using one-way ANOVA. *P < 0.05, **P < 0.01 in multivariate
analysis using multinomial logistic regression
Fig. 6 IL-8 producing PBMC and response to anti-VEGF therapy. Percentage of IL-8 producing PBMCs of controls and nAMD patients not, partially and
completely responding to anti-VEGF therapy under non-stimulated condition (a), and following PMA/ionomycin stimulation (b). Controls:n= 27, non-
responders: n= 2, partial responders: n= 16, complete responders: n= 10; mean + SEM; #P< 0.05, in univariate analysis using independent samples t test
Lechner et al. Journal of Neuroinflammation  (2017) 14:42 Page 9 of 12
responders (although the difference was not statistically
significant, possibly due to insufficient patient numbers).
The results suggest that apart from VEGF, IL-8 may be
another important pro-angiogenic factor in nAMD. Fur-
ther studies using larger patient samples are necessary to
confirm the role of IL-8 in nAMD and the response to
anti-VEGF therapy.
Previously, we reported increased levels of neutrophils
in nAMD patients [16]. IL-8 is a strong chemotactic
factor for neutrophils [33]. Although how neutrophils
are involved in nAMD is not known, the high levels of
IL-8 by PBMC may contribute to increased levels of
circulating neutrophils in nAMD.
CCL2 plays a crucial role in monocyte and lymphocyte
trafficking under inflammatory conditions [34]. Compel-
ling evidence suggests that the CCL2/CCR2 pathway
may play a role in AMD pathogenesis. The aqueous
humour of nAMD patients contains high levels of CCL2
[35], and CCL2 expression was detected in atrophic
lesions in AMD patients [36]. Monocytes from nAMD
patients were shown to express higher levels of CCR1
and CCR2 [14]. Importantly, experimental studies have
shown that CCL2 can promote CNV formation through
enhanced recruitment of myeloid cells [37]. In this
study, we found that PBMCs from nAMD patients pro-
duced higher levels of CCL2, although there was no dif-
ference in the serum CCL2 concentration between
nAMD patients and controls (which is in line with a pre-
vious report [14]). Our results indicate that CCL2 pro-
duction by infiltrating immune cells might be related to
macular lesion development in nAMD.
In a previous study, we reported increased STAT3 acti-
vation in circulating monocytes from nAMD patients
[15], which may contribute to increased VEGF produc-
tion by PBMC observed in the current study. IL-6 is one
of the major cytokines that can active the JAK1/STAT3
pathway. Interestingly, in this study, we found an in-
creased percentage of IL-6 producing CD11b+CD3−
monocytes in nAMD patients compared to that in
controls. A previous study has reported an association
between circulating levels of IL-6 (~6 pg/ml) and AMD
progression [38]; however, in our study, the serum levels
of IL-6 were below the detection limit, i.e. 0.3 pg/ml in
both patients and controls. The role of IL-6 in nAMD
warrants further investigation.
The development of macular fibrosis results in irre-
versible vision loss in nAMD [39], although the under-
lying mechanisms remain ill-defined and there is no
treatment modality for it. Even following the introduc-
tion of anti-VEGF therapies, which have improved visual
outcomes markedly, fibrosis remains an integral compo-
nent of the macular lesion and has been shown to be
associated with the poorer outcomes compared to eyes
without fibrosis [40–42]. In the present study, we
observed increased levels of IL-8 and CCL2 in PBMCs
from nAMD patients without fibrosis suggesting that IL-
8 and CCL2 from PBMCs might reduce the risk. Inter-
estingly, IL-8 and CCL2 have previously been shown to
have pro-fibrotic effects in various tissues including the
lung [43, 44], kidney [45, 46], liver [47] and skin [48, 49].
The tissue-specific role of CCL2 and IL-8 in fibrosis has
not been reported before. Therefore, it is possible that
those chemokines may have anti-fibrotic effects in the
retinal microenvironment. Other chemokines such as
CXCL10 have previously been shown to mediate tissue-
specific pro- (e.g. in the liver) [50] as well as anti-fibrotic
effects (e.g. in the lung) [51]. Further studies are neces-
sary to investigate the role of CCL2 and IL-8 in fibrosis
in nAMD.
Macular atrophy (MA) is due to the degeneration of
RPE and overlying photoreceptors although the under-
lying mechanism remains poorly defined. MA and
nAMD co-exist in many patients, particularly following
long-term anti-VEGF therapy [1]. In the present study,
67% of patients exhibited MA during their follow-up.
PBMC from the patients who had MA produced in-
creased levels of VEGF. Previous studies have shown
that enhanced MA progression in nAMD patients is as-
sociated with anti-VEGF injections [52]. In the present
study, a numerically greater proportion of patients with
MA had received more anti-VEGF injections than those
without but this did not reach statistical significance (P
= 0.056). The reasons for the higher prevalence of MA
in eyes undergoing anti-VEGF treatment is not entirely
explicable by a higher rate of exposure to VEGF but may
also reflect destruction of the macular tissues by a more
active CNV lesion and hence the higher number of
treatments required in this group [41].
The strengths of the present study include independent
grading of AMD, fibrosis, MA and anti-VEGF responsive-
ness and systematic and extensive exploration of cytokine
production and secretion by PBMCs in nAMD as well as
in patients with fibrosis, MA and partially or completely
responding to anti-VEGF treatment.
One of the limitations of this study is that patients
were recruited to the study at different stages of nAMD,
and therefore, some patients classified as not having
macular fibrosis or atrophy may do so over time.
Secondly, 98% of patients were on anti-VEGF treatment
at the time of enrolment which might have an effect on
circulating immune cells although we did not find any
correlation between variables analysed and the number
of anti-VEGF injections received. Despite our efforts to
recruit age-matched controls, there was a significant
difference in age between nAMD patients and controls
in one of our experimental analyses (serum analysis,
experiment 1). Finally, some of the analyses were done with
small patient numbers (e.g. patients without MA n = 17,
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partial responders n = 16, complete responders n = 10)
and larger confirmatory studies are necessary to verify
our results.
Conclusion
In summary, our study shows that PBMCs, especially
monocytes, appear to be pre-conditioned to an inflam-
matory and angiogenic phenotype in nAMD patients.
They may contribute to dysregulated retinal inflamma-
tion [20] and CNV formation after recruitment to the
macula by secreting elevated levels of IL-8, CCL2 and
VEGF. Our research also uncovered a link between
PBMC released IL-8 and CCL2 and macular fibrosis in
nAMD. Further studies are necessary to understand
whether IL-8 and CCL2 might be targeted for nAMD
management.
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